<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709017</url>
  </required_header>
  <id_info>
    <org_study_id>297-402-00002</org_study_id>
    <nct_id>NCT03709017</nct_id>
  </id_info>
  <brief_title>Iclusig PMS in CML or Ph+ALL Patients</brief_title>
  <official_title>Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the &quot;Risk Management Plan&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Marketing Surveillance (PMS) of Iclusig® Tablets in accordance with Korean
      regulations on Risk Management Plan (RMP). This PMS is to assess safety and effectiveness
      data after administrating Ponatinib (of Iclusig® Tablets) per approved indication, usage and
      dosage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate and the number of Adverse Events (AE)/Adverse Drug Reactions (ADR), Serious AE/ADR, Unexpected AE/ADR</measure>
    <time_frame>until 14 days after last administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who satisfy CHR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who satisfy CHR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who satisfy MCyR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who satisfy MCyR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects who satisfy MMR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who satisfy MMR</measure>
    <time_frame>at 3 months and 6 months from administration</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Iclusig 45mg, 15mg</description>
    <other_name>Iclusig</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are prescribed Iclusig® tablets and provide written informed consent will be
        enrolled. The number of patients to be enrolled by each investigator will vary.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are prescribed Iclusig® per Prescribing information (PI) for the purpose
             of treatment

        Exclusion Criteria:

          -  Patients with known or suspected hypersensitivity to ponatinib or to any ingredient of
             the drug

          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JUHEE JEON</last_name>
    <phone>82-10-2388-5367</phone>
    <email>jjh513@otsuka.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kosin University Gaspel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hosup Lee</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

